A Phase III, International, Randomized, Double-Blind, Parallel-Group, Multi-Center Study to Assess the Efficacy of ZACTIMA™ Versus Erlotinib (Tarceva®) in Patients With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC) after Failure of at least One Prior Chemotherapy